

# A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in *Acinetobacter baumannii*.

**Author;** Stamatis Karakonstantis

**Affiliations;**

1. Internal Medicine Department, General Hospital of Heraklion Venizeleio, Heraklion, Crete, Greece, postal code 71409

2. School of medicine, University of Crete, Heraklion, Crete, Greece, postal code 71410

**Contact information;**

Address; Internal Medicine Department, General Hospital of Heraklion Venizeleio, Heraklion, Crete, Greece, postal code 71409

Telephone; +30-6940100298

E-mail; [stamatiskarakonstantis@gmail.com](mailto:stamatiskarakonstantis@gmail.com)

ORCID; 0000-0002-2643-3184

## Abstract

The potential of *A. baumannii* for acquired resistance to last resort antibiotics (colistin and tigecycline) during treatment has important clinical implications, especially when dealing with patients failing to improve despite treatment with an active antimicrobial. However, the relevant literature remains scattered. Therefore, a systematic search was conducted in PubMed and Scopus. Several studies reported emergence of resistance to colistin or tigecycline during treatment, in most cases (86%) resulting in persistent or recurrent infections, especially in cases of emergent resistance without fitness cost. Lipopolysaccharide modification in the case of colistin and overexpression of efflux pumps in the case of tigecycline were the main mechanisms of resistance. Emergent colistin resistance is often associated with fitness cost resulting in re-emergence of the fitter and more virulent colistin susceptible strain after cessation of antibiotic pressure. Prospective studies are needed to determine the frequency of emergent resistance during treatment and its impact on patient outcomes.

**Keywords;** Acinetobacter, baumannii, colistin, tigecycline, resistance, in vivo

## Introduction

Carbapenem-resistance in *Acinetobacter baumannii* is rising and in many regions, especially in Europe and the Middle East, the majority of *A. baumannii* strains are resistant to carbapenems [1, 2]. The main treatment options for carbapenem-resistant *A. baumannii* include colistin, tigecycline and more recently cefiderocol if available [3]. Other options are aminoglycosides, trimethoprim-sulfamethoxazole and sulbactam but resistance to these agents is common [3]. Furthermore, resistance even to colistin and tigecycline is rising, and pandrug-resistant isolates are increasingly being reported [4].

Even with in vitro active treatment with the above antimicrobials mortality remains high [3]. The genomic plasticity and heteroresistance of *A. baumannii* facilitate the emergence of resistance to last resort antimicrobials during treatment [5], which could explain clinical/microbiological failure in some cases, but has not to my knowledge been previously reviewed, and the relevant literature remains scattered.

Of note is that resistant *A. baumannii* mutants developed in vitro may differ significantly from *A. baumannii* strains that develop resistance in vivo during treatment. For example, colistin resistance developed in vitro is usually mediated by lipopolysaccharide (LPS) loss (compared to lipid A modifications with in vivo emergence of resistance), which is associated with higher fitness costs and often reversal of susceptibility to other antibiotics [6, 7]. Therefore, studies of in vivo emergence of resistance during treatment are more clinically relevant.

Considering the above, the aim of this review is to systematically search and consolidate the literature on; a) the occurrence of in vivo emergence of resistance in *A. baumannii* to colistin and tigecycline, b) the mechanisms of emergent resistance, c) whether such resistance is transient and associated with fitness cost, d) the presence of cross-resistance between last resort antibiotics, and d) the impact of emergent resistance on treatment failure.

## Methods

**Search strategy;** The following search was conducted in MEDLINE (PubMed) and Scopus, from inception to April 2020; baumannii AND (serial OR sequential OR subsequent OR successive OR consecutive OR succeeding OR "same patient" OR "same patients" OR "single patient" OR "in vivo emergence" OR "during treatment" OR "during therapy" OR isogenic OR paired OR pair OR pairs) AND (resistance OR resistant). Retrieved articles were initially screened based on their

titles and abstracts. The full texts of potentially eligible articles were then reviewed. The search was supplemented by reference tracking of included papers.

**Eligibility criteria;** Any study reporting emergence of resistance to colistin and/or tigecycline in sequential *A. baumannii* isolates from the same patient was eligible. In vitro studies, studies in animals and articles written in languages other than English were not eligible for this review.

**Data items;** The following data were collected from each study; method of antimicrobial susceptibility testing, exposure to colistin/tigecycline before emergence of resistance, mechanisms of emergent resistance, whether emergent resistance was associated with reduced fitness or virulence, the presence of cross-resistance between last resort antibiotics (colistin, tigecycline, minocycline, amikacin, gentamicin, tobramycin, trimethoprim/sulfamethoxazole, ampicillin/sulbactam), availability of molecular analyses to confirm the same origin (versus cross-infection by new strain) of paired isolates from the same patient, stability of resistance after withdrawal of antimicrobials, effect of emergent resistance on treatment failure and in-hospital mortality. Extraction of these data from eligible studies was performed twice.

**Definitions;** Emergent resistance was considered to be responsible for treatment failure when associated with persistent or recurrent symptoms and/or signs of infection necessitating further treatment. Cross-resistance was defined as simultaneous emergence of resistance to >1 last resort antimicrobial and mediated by a common mechanism.

**Synthesis of results;** A qualitative presentation and synthesis of the characteristics and findings of retrieved studies was conducted.

## Results

### Study selection and study characteristics

The flow chart of the review is depicted in Figure 1. The main characteristics and findings of included studies (n=39 [8-46]) are summarized in Table 1 and Supplementary Table 1. The strains reported in 7 studies [14, 15, 18, 20, 21, 24, 41] were duplicates of strains reported in prior studies [13, 17, 19, 23, 42] but these studies were still included because complementary data relevant to the review were provided in the later studies. Excluding duplicates, in vivo emergence of resistance to colistin was reported in n=55 patients [11, 16-20, 22-29, 31-38, 40-44, 46] and to tigecycline in n=16 patients [8-10, 12-15, 23, 30, 32, 33, 39, 45].

### Exposure to colistin/tigecycline before emergent resistance

In most cases (colistin n=52/55, tigecycline n=9/16) resistance emerged during or after treatment with the same antibiotic [8, 10, 11, 13-15, 17-30, 32-38, 40-43, 45, 46]. In one case, resistance to both tigecycline and tobramycin emerged during treatment with tobramycin, associated with overexpression of *adeB* efflux pump [12]. In few cases (tigecycline n=6, colistin n=2) it was not reported if treatment with colistin/tigecycline preceded the emergence of resistance. In one case a colistin-resistant *A. baumannii* strain emerged without prior exposure to colistin [44].

### Cross-resistance between last resort antibiotics

Colistin resistance was not associated with cross-resistance to other last resort antibiotics (Supplementary Table 1). Emergent resistance to tigecycline may be associated with decreased susceptibility to aminoglycosides [8, 9, 12, 39] and minocycline [39], potentially mediated by overexpression of *adeB* efflux pump [9, 12, 39] (Supplementary Table 1).

In 2 cases resistance to both colistin and tigecycline emerged during treatment [23, 33]. In one of these cases exposure to both tigecycline and colistin preceded emergence of resistance [33], while in the other case whether exposure to tigecycline or aminoglycosides preceded the emergence of resistance was not clarified [23]. Mutation in *pmrB* (conferring colistin resistance) were found in both cases, but the potential mechanisms of tigecycline resistance were not evaluated [23, 33].

In contrast to colistin-resistant mutants developed in vitro [29], colistin resistance emerging in vivo did not generally result in increased susceptibility to other antibiotics (Supplementary Table 1), although reversal of susceptibility to ampicillin/sulbactam was noted in 4 cases [17, 23, 41].

### Mechanisms of emergent resistance

The mechanism of emergent colistin resistance was evaluated in n=49 cases (Table 1). In most cases (n=44) a variety of mutations were noted in the *pmrCAB* locus (predominantly *pmrB*) [16, 18, 20, 23, 25-29, 31-33, 36, 38, 40, 41, 44, 46], resulting in upregulation of *pmr* genes [16, 23, 25, 27, 36, 44, 46]. The locus regulates a phosphoethanolamine (pEtN) transferase coded by *pmrC*, that by modifying the lipid A component of LPS reduces its negative charge and decreases the binding of the positively charged colistin. Upregulation of *eptA*, a *pmrC* homologue, which also codes for a pEtN transferase, was reported in 2 cases [37, 44]. Mutations in genes essential for synthesis of lipid A component of LPS, often observed in colistin-resistant *A. baumannii* developed in vitro [6, 7, 29], were reported in only one case in vivo [36].

The mechanism of tigecycline resistance was evaluated in n=11 cases [9, 12, 14, 15, 30, 39, 45]. Upregulation of *adeABC* efflux pumps was found in 8 cases, caused by mutations in regulatory genes *AdeS* [9, 14, 15, 39], *AdeN* [39], and *AdeR* [12]. Other mechanisms, not involving the *adeABC* pumps, were proposed in 3 other cases [30, 45] (Table 1).

## Is in vivo emergence of resistance transient and associated with fitness cost?

The impact of emergent colistin resistance on fitness and/or virulence was examined in n=17 cases [18, 21, 24, 25, 27-29, 33, 37, 38, 44]. In 10 cases (59%) emergence of colistin resistance was associated with fitness cost and/or lower virulence based on in vitro growth [18, 21, 24, 25, 27] and/or in vivo infection models [18, 21, 24].

The cost associated with colistin resistance may result in re-emergence of colistin-susceptible *A. baumannii* after withdrawal of colistin, as demonstrated in 7 patients [25, 28, 32, 41]. The mechanisms of loss of colistin resistance were examined in one study by whole genome sequencing and comparison between sequential *A. baumannii* isolates from the same patients (susceptible before exposure to colistin, resistant during treatment, and susceptible after withdrawal of colistin) [25]. In all cases emergent resistance was due to mutations in *pmrB*. The loss of resistance following withdrawal of colistin resulted from; a) additional compensatory mutations in *pmr* genes (1 case), b) re-emergence of the ancestral susceptible strain based on an identical *pmr* genotype (2 cases), c) cross-infection by a different strain based on a different pulsotype (1 case).

However, colistin resistance may often emerge without apparent fitness cost (based on growth curves [25, 28, 29, 33, 37, 38, 44]) or with unaffected [28] or even increased [24, 33, 44] virulence (based on in vivo infection models [24, 28, 44], or in vitro studies of virulence [33]). For example, a stably resistant strain was described in one study and its transmission between patients was demonstrated [25].

Generally, *pmrB* mutations (the predominant mechanism responsible for in vivo emergence of resistance) are associated with less fitness cost compared to LPS loss (typically observed only in mutants developed in vitro) [6, 7, 38]. It has also been hypothesized that in the long term

fitness-compensatory mutations may increase the stability and persistence of colistin-resistant *A. baumannii* strains [19, 25, 28]. For example, increasing fitness and virulence was demonstrated in one patients with multiple sequential colistin-resistant *A. baumannii* isolates [24].

Re-emergence of susceptibility to tigecycline was not reported in any of the reviewed studies. The effect of emergent tigecycline resistance on fitness and virulence (based on the *G. mellonella* model) was evaluated in 2 cases; the susceptible strain outcompeted its susceptible counterpart in one case, while the opposite was found in the second case [15]. Regardless of fitness/virulence differences both tigecycline-susceptible and tigecycline-resistant strains were pathogenic [15].

#### Does emergent resistance explain treatment failure?

The impact of emergent resistance was evaluable in 28 cases; in 86% (24/28) emergent resistance was associated with persistent or recurrent infection [8, 11, 12, 17, 22, 23, 28, 32, 37, 38, 40, 43, 46] (Table 1), while in 14% (4/28) emergent resistance did not require any further treatment [13, 19, 27, 43], possibly due to reduced virulence of the resistant strains [15, 19, 27]. Treatment failure appears to be more common when emergent resistance is not associated with reduced fitness/virulence, but even strains with reduced fitness may be associated with treatment failure (Supplementary Table 2). In-hospital mortality was 42% (14/33) among the 33 cases evaluable for this outcome (Table 1).

#### Cross-infection by new strain versus in vivo emergence of resistance

Isolation of a resistant strain from a patient previously colonized/infected by a susceptible strain has two possible explanations; a) emergence of resistance in the same strain, or b) cross-infection by a different resistant strain. The fact that in most cases resistance to colistin/tigecycline



emerged during/after treatment, in combination with molecular methods available in most of the included studies (Table 1), support that in most cases resistance emerged from the same strain as a result of antibiotic pressure.

## Discussion

### Summary of the main findings

Several case studies reported the emergence of resistance to colistin or tigecycline during treatment of *A. baumannii* infections, which was in most cases associated with persistent or recurrent infection. Cross-resistance was not observed between colistin and other last resort antibiotics, but tigecycline may be associated with cross-resistance to aminoglycosides and minocycline. If resistance is associated with fitness cost, which is common for colistin, the ancestral susceptible strain may re-emerge after withdrawal of antibiotic pressure. Based on the limited available data treatment failure appears more common when resistance is not associated with reduced fitness/virulence, but this observation requires confirmation in larger cohorts.

### How common is emergent resistance during treatment?

Considering that this review was based on case reports or small series the frequency of emergent resistance during treatment could not be investigated. Based on cohorts of patients being treated for *A. baumannii* infections emergent resistance appears to be uncommon (5% [47], 0% [48], 6.4% [49], 13.5% [25]).

However, several factors could have underestimated the frequency of emergent resistance in these studies; (a) lack of culture after emergence of resistance due to patient death before culture could be obtained, (b) lack of culture after emergence of resistance due to patient

improvement (patients may improve despite persistent colonization and emergence of resistance), (c) potentially low sensitivity of cultures in pneumonia and lack of sampling of other potential sites of *A. baumannii* colonization, (d) false colistin susceptibility (for example 20% of the isolates in one of the above trials initially classified as colistin-susceptible according to Vitek-2 or E-test were then found to be resistant using broth microdilution [50]).

To evaluate the frequency and impact of emergent resistance during treatment prospective studies are needed with repeated cultures from the site of infection (and ideally from all potential sites of *A. baumannii* colonization) before, during and after treatment. Such studies should ideally incorporate molecular methods to determine the mechanisms of resistance and the clonal relatedness of sequential isolates from each patient, as well as methods to examine the effect of emergent resistance on fitness and virulence and correlate this with treatment outcomes.

### Potential implications of transient resistance

Rapid emergence of colistin resistance from a heteroresistant population during treatment may allow *A. baumannii* to survive under antibiotic pressure. When antibiotic pressure ceases the fitter and more virulent ancestral susceptible strain may re-emerge [25], potentially resulting in re-infection in the same patient or transmission to other patients. The development of persister cells (viable but non-dividing cells that can survive lethal doses of antibiotics and are able to re-emerge after cessation of antibiotic pressure) during treatment may explain this observation [51]. Of note is that colistin heteroresistance is likely to be missed by methods such as Vitek 2 or E-test [25, 35, 50] and may even be missed with broth microdilution [32, 52]. Therefore, the true prevalence of in vivo colistin resistance may be underestimated and its impact under-recognized.

## Limitations

The main limitation of this review is that it is based solely on case reports or small case series. Furthermore, despite the fact that resistance emerged during treatment and the availability of molecular methods to support the same origin of sequential isolates, the possibility of cross-infection or mixed infection by more than one strain cannot be completely ruled out. Moreover, the method of susceptibility testing was not reported in some studies or unreliable methods were used (e.g. E-test for colistin) (Table 1). Finally, comparison of the genomic and transcriptomic signatures between resistant and susceptible *A. baumannii* strains is more complex than presented here [30, 36, 44] but beyond the scopes of this review.

## Conclusions

Several studies have described the in-vivo emergence of resistance to colistin or tigecycline during treatment of *A. baumannii* infections, often resulting in persistent or recurrent infection. The frequency and impact of emergent resistance during treatment requires further study in appropriately designed prospective studies, as discussed above. This has important clinical implications, especially when dealing with patients not responding to apparently active (based on initial antimicrobial susceptibility results) antibiotics. Furthermore, the role of combination therapy for *A. baumannii* may require reconsideration, despite negative results of recent meta-analyses and trials which combined colistin with in-vitro inactive agents (meropenem, sulbactam, fosfomycin, rifampicin) [53-56]. Combination with a second active agent (e.g. tigecycline [57]) or the potential of other synergistic combinations [34, 58-60] requires further study.

## Declarations

**Conflict of interest;** I have no conflict of interest to declare

**Funding;** No external funding was received for this work

## References

1. Lob SH, Hoban DJ, Sahn DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents*. 2016;47(4):317-23.
2. Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. *Euro Surveill*. 2018;23(46):1800516.
3. Piperaki ET, Tzouveleki LS, Miriagou V, Daikos GL. Carbapenem-resistant *Acinetobacter baumannii*: in pursuit of an effective treatment. *Clinical Microbiology and Infection*. 2019;25(8):951-7.
4. Karakostas S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. *Journal of Antimicrobial Chemotherapy*. 2019.
5. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of *Acinetobacter baumannii*: clinical reports, mechanisms and antimicrobial strategies. *Journal of Antimicrobial Chemotherapy*. 2012;67(7):1607-15.
6. Da Silva GJ, Domingues S. Interplay between Colistin Resistance, Virulence and Fitness in *Acinetobacter baumannii*. *Antibiotics (Basel)*. 2017;6(4).
7. Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2014;58(1):518-26.
8. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of *Acinetobacter baumannii* resistance to tigecycline. *Pharmacotherapy*. 2007;27(8):1198-201.
9. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. *Journal of Antimicrobial Chemotherapy*. 2007;59(5):1001-4.
10. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. *Clinical Infectious Diseases*. 2008;46(4):567-70.
11. David MD, Gill MJ. Potential for underdosing and emergence of resistance in *Acinetobacter baumannii* during treatment with colistin. *Journal of Antimicrobial Chemotherapy*. 2008;61(4):962-4.
12. Higgins PG, Schneiders T, Hamprecht A, Seifert H. In vivo selection of a missense mutation in *adeR* and conversion of the novel *blaOXA-164* gene into *blaOXA-58* in carbapenem-resistant

- Acinetobacter baumannii isolates from a hospitalized patient. *Antimicrobial Agents and Chemotherapy*. 2010;54(12):5021-7.
13. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy*. 2010;65(8):1589-93.
  14. Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF et al. Whole-genome comparison of two *Acinetobacter baumannii* isolates from a single patient, where resistance developed during tigecycline therapy. *Journal of Antimicrobial Chemotherapy*. 2011;66(7):1499-503.
  15. Hornsey M, Wareham DW. Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of *Acinetobacter baumannii*. *Scientific Reports*. 2018;8(1):4234.
  16. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the pmrAB two-component regulatory system. *Antimicrobial Agents and Chemotherapy*. 2011;55(7):3370-9.
  17. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. *Acinetobacter baumannii* resistant to colistin alters its antibiotic resistance profile: a case report from Spain. *Journal of Infectious Diseases*. 2011;204(7):1147-8.
  18. Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. Colistin resistance in a clinical *Acinetobacter baumannii* strain appearing after colistin treatment: effect on virulence and bacterial fitness. *Antimicrobial Agents and Chemotherapy*. 2013;57(9):4587-9.
  19. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. *Acinetobacter baumannii* resistant to colistin with impaired virulence: a case report from France. *Journal of Infectious Diseases*. 2011;204(7):1146-7.
  20. Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant *Acinetobacter baumannii* isolate from Marseille, France. *Antimicrobial Agents and Chemotherapy*. 2013;57(1):592-6.
  21. Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J-M et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of *Acinetobacter baumannii* in a rat model of pneumonia. *Antimicrobial Agents and Chemotherapy*. 2013;57(10):5120-1.
  22. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silveira FP et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant *Acinetobacter baumannii*: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. *Diagnostic Microbiology and Infectious Disease*. 2011;70(2):246-52.
  23. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M et al. Emergence of colistin-resistance in extremely drug-resistant *Acinetobacter baumannii* containing a novel pmrCAB operon during colistin therapy of wound infections. *Journal of Infectious Diseases*. 2013;208(7):1142-51.
  24. Jones CL, Singh SS, Alamneh Y, Casella LG, Ernst RK, Lesho EP et al. In Vivo Fitness Adaptations of Colistin-Resistant *Acinetobacter baumannii* Isolates to Oxidative Stress. *Antimicrobial Agents and Chemotherapy*. 2017;61(3):e00598-16.
  25. Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray PR, Segre JA. Genomic insights into the fate of colistin resistance and *Acinetobacter baumannii* during patient treatment. *Genome Research*. 2013;23(7):1155-62.

26. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. In vivo emergence of colistin resistance in *Acinetobacter baumannii* clinical isolates of sequence type 357 during colistin treatment. *Diagnostic Microbiology and Infectious Disease*. 2014;79(3):362-6.
27. Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2014;58(2):828-32.
28. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant *Acinetobacter baumannii*. *Diagnostic Microbiology and Infectious Disease*. 2015;82(3):222-6.
29. Lim TP, Ong RT, Hon PY, Hawkey J, Holt KE, Koh TH et al. Multiple Genetic Mutations Associated with Polymyxin Resistance in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2015;59(12):7899-902.
30. Liu L, Cui Y, Zheng B, Jiang S, Yu W, Shen P et al. Analysis of tigecycline resistance development in clinical *Acinetobacter baumannii* isolates through a combined genomic and transcriptomic approach. *Scientific Reports*. 2016;6:26930.
31. Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD. Genome dynamics of multidrug-resistant *Acinetobacter baumannii* during infection and treatment. *Genome Medicine*. 2016;8(1):26.
32. Choi HJ, Kil MC, Choi JY, Kim SJ, Park KS, Kim YJ et al. Characterisation of successive *Acinetobacter baumannii* isolates from a deceased haemophagocytic lymphohistiocytosis patient. *International Journal of Antimicrobial Agents*. 2017;49(1):102-6.
33. Dahdouh E, Gómez-Gil R, Sanz S, González-Zorn B, Daoud Z, Mingorance J et al. A novel mutation in *pmrB* mediates colistin resistance during therapy of *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents*. 2017;49(6):727-33.
34. Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A et al. Polymyxin-resistant, carbapenem-resistant *Acinetobacter baumannii* is eradicated by a triple combination of agents that lack individual activity. *Journal of Antimicrobial Chemotherapy*. 2017;72(5):1415-20.
35. Savari M, Ekrami A, Shoja S, Bahador A. Acquisition of Tn6018-3' CS regions increases colistin MICs against *Acinetobacter baumannii* isolates harboring new variants of AbaRs. *Folia Microbiologica*. 2017;62(5):373-9.
36. Cafiso V, Stracquadanio S, Lo Verde F, Gabriele G, Mezzatesta ML, Caio C et al. Colistin Resistant *A. baumannii*: Genomic and Transcriptomic Traits Acquired Under Colistin Therapy. *Frontiers in Microbiology*. 2018;9:3195.
37. Deveson Lucas D, Crane B, Wright A, Han ML, Moffatt J, Bulach D et al. Emergence of High-Level Colistin Resistance in an *Acinetobacter baumannii* Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS. *Antimicrobial Agents and Chemotherapy*. 2018;62(7).
38. Farshadzadeh Z, Taheri B, Rahimi S, Shoja S, Pourhajibagher M, Haghghi MA et al. Growth Rate and Biofilm Formation Ability of Clinical and Laboratory-Evolved Colistin-Resistant Strains of *Acinetobacter baumannii*. *Frontiers in Microbiology*. 2018;9:153.
39. Gerson S, Nowak J, Zander E, Ertel J, Wen Y, Krut O et al. Diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with tigecycline resistance in *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy*. 2018;73(6):1501-8.

40. Jaidane N, Naas T, Mansour W, Radhia BB, Jerbi S, Boujaafar N et al. Genomic analysis of in vivo acquired resistance to colistin and rifampicin in *Acinetobacter baumannii*. *International Journal of Antimicrobial Agents*. 2018;51(2):266-9.
41. Mustapha MM, Li B, Pacey MP, Mettus RT, McElheny CL, Marshall CW et al. Phylogenomics of colistin-susceptible and resistant XDR *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy*. 2018;73(11):2952-9.
42. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK et al. Colistin-resistant *Acinetobacter baumannii*: beyond carbapenem resistance. *Clinical Infectious Diseases*. 2015;60(9):1295-303.
43. Saun TJ, Rogers AD, Leis JA, Cartotto R. The Use of Intravenous and Inhaled Colistin Therapy During a Burn Center Outbreak of Multidrug-Resistant *Acinetobacter baumannii*. *J Burn Care Res*. 2018;39(6):1029-36.
44. Gerson S, Betts JW, Lucaßen K, Nodari CS, Wille J, Josten M et al. Investigation of Novel *pmrB* and *eptA* Mutations in Isogenic *Acinetobacter baumannii* Isolates Associated with Colistin Resistance and Increased Virulence In Vivo. *Antimicrobial Agents and Chemotherapy*. 2019;63(3).
45. Cheng J, Kesavan DK, Vasudevan A, Cai W, Wang H, Su Z et al. Genome and Transcriptome Analysis of *A. baumannii*'s "Transient" Increase in Drug Resistance under Tigecycline Pressure. *J Glob Antimicrob Resist*. 2020.
46. Marano V, Marascio N, Pavia G, Lamberti AG, Quirino A, Musarella R et al. Identification of *pmrB* mutations as putative mechanism for colistin resistance in *A. baumannii* strains isolated after in vivo colistin exposure. *Microbial Pathogenesis*. 2020;142:104058.
47. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infectious Diseases*. 2018;18(4):391-400.
48. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P et al. Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant *Acinetobacter baumannii*: A Multicenter, Randomized Clinical Trial. *Clinical Infectious Diseases*. 2013;57(3):349-58.
49. Jean S-S, Hsieh T-C, Lee W-S, Hsueh P-R, Hsu C-W, Lam C. Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium? *Medicine*. 2018;97(39):e12278-e.
50. Dickstein Y, Lellouche J, Dalak Amar MB, Schwartz D, Nutman A, Daitch V et al. Treatment outcomes of colistin and carbapenem-resistant *Acinetobacter baumannii* infections: an exploratory subgroup analysis of a randomized clinical trial. *Clinical Infectious Diseases*. 2018.
51. Wong FH, Cai Y, Leck H, Lim TP, Teo JQ, Lee W et al. Determining the Development of Persisters in Extensively Drug-Resistant *Acinetobacter baumannii* upon Exposure to Polymyxin B-Based Antibiotic Combinations Using Flow Cytometry. *Antimicrobial Agents and Chemotherapy*. 2020;64(3).
52. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE et al. Heteroresistance to colistin in multidrug-resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2006;50(9):2946-50.
53. Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. *International Journal of Antimicrobial Agents*. 2018;51(4):535-47.

54. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2017;72(1):29-39.
55. Cheng IL, Chen YH, Lai CC, Tang HJ. Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials. *J Clin Med*. 2018;7(8).
56. Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with *Acinetobacter baumannii* infection: A systematic review and meta-analysis. *International Journal of Antimicrobial Agents*. 2019;53(4):383-400.
57. Cai X, Yang Z, Dai J, Chen K, Zhang L, Ni W et al. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant *Acinetobacter baumannii* in an in vitro pharmacodynamic model. *International Journal of Antimicrobial Agents*. 2017;49(5):609-16.
58. Assimakopoulos SF, Karamouzou V, Lefkaditi A, Sklavou C, Kolonitsiou F, Christofidou M et al. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant *Acinetobacter baumannii*: a case series study. *Le Infezioni in Medicina*. 2019;27(1):11-6.
59. Bae S, Kim M-C, Park S-J, Kim HS, Sung H, Kim M-N et al. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*. 2016;60(11):6774-9.
60. Poulakou G, Renieris G, Sabrakos L, Zarkotou O, Themeli-Digalaki K, Perivolioti E et al. Daptomycin as adjunctive treatment for experimental infection by *Acinetobacter baumannii* with resistance to colistin. *International Journal of Antimicrobial Agents*. 2018.



Figure 1; Flow chart of the review




Table 1; Summary of characteristics and findings of included studies

| First author, Year           | Emergent resistance to (n <sup>a</sup> ); | Method of susceptibility testing <sup>b</sup> | Mechanisms of resistance <sup>c</sup>  | Fitness cost | Molecular methods <sup>d</sup> | Effect on treatment failure <sup>e</sup> | Outcome          |
|------------------------------|---|---|--|--------------|--------------------------------|--|------------------|
| Reid GE, 2007 [8]            | TGC (n=1) <sup>f</sup>                    | E-test  | NR   | NR           | No                             | Yes                                      | Discharged       |
| Ruzin A, 2007 [9]            | TGC (n=1) <sup>g</sup>                    | E-test  | Disruption of <i>AdeS</i> by ISAb <sub>1</sub> resulting in overexpression of <i>adeABC</i> efflux pumps | NR           | Ribotyping                     | NR                                       | NR               |
| Anthony KB, 2008 [10]        | TGC (n=1) <sup>f</sup>                    | E-test  | NR   | NR           | No                             | Unclear <sup>h</sup>                     | Discharged       |
| David MD, 2008 [11]          | COL (n=1) <sup>f</sup>                    | agar dilution                                 | NR   | NR           | No                             | Yes                                      | Died             |
| Higgins PG, 2010 [12]        | TGC (n=1) <sup>i</sup>                    | E-test  | <i>adeR</i> mutation (D20N) resulting in overexpression of <i>adeB</i> efflux pump                       | NR           | PFGE, rep-PCR                  | Yes                                      | Died             |
| Hornsey M, 2010 [13-15]      | TGC (n=2) <sup>f</sup>                    | agar dilution, E-test                         | <i>adeS</i> mutations (A98V, S8R) resulting in overexpression of <i>adeABC</i> efflux pumps              | Yes (1/2)    | PFGE, WGS, SNPs                | Yes (1/2)                                | Discharged (2/2) |
| Beceiro A, 2011[16]          | COL (n=1) <sup>g</sup>                    | agar dilution, E-test                         | <i>pmrB</i> mutation (L87F)  | NR           | PFGE                           | NR                                       | NR               |
| López-Rojas, 2011 R [17, 18] | COL (n=1) <sup>f</sup>                    | NR  | <i>pmrA</i> mutation (M12K)  | Yes          | rep-PCR                        | Yes                                      | Discharged       |
| Rolain JM, 2011 [19-21]      | COL (n=1) <sup>f</sup>                    | NR  | <i>pmrA</i> mutation (E8D)   | Yes          | PGFE, WGS, SNPs, MLST          | No                                       | Discharged       |
| Shields RK, 2011 [22]        | COL (n=3) <sup>f</sup>                    | E-test  | NR   | NR           | No                             | Yes (3/3)                                | Died (3/3)       |

| First author, Year           | Emergent resistance to (n <sup>a</sup> );            | Method of susceptibility testing <sup>b</sup> | Mechanisms of resistance <sup>c</sup>  | Fitness cost | Molecular methods <sup>d</sup>                           | Effect on treatment failure <sup>e</sup> | Outcome                      |
|------------------------------|--|---|--|--------------|--|--|------------------------------|
| Lesho E, 2013 [23, 24]       | COL (n=2) <sup>f</sup><br>COL+TGC (n=1) <sup>g</sup> | broth microdilution                           | <i>pmrA</i> mutation (E8D)<br><i>pmrB</i> mutations (S17R, Y116H)<br>mechanism of TGC resistance was not evaluated | Yes (1/1)    | PFGE, optical genome mapping, SNPs phylogenetic analysis | Yes (2/2)                                | “successfully treated” (2/2) |
| Snitkin ES, 2013 [25]        | COL (n=4) <sup>f</sup>                               | broth microdilution                           | <i>pmrB</i> mutations (P233S, indel AAT at 69, R263C, T187P, A226T, L271R)<br><i>pmrC</i> mutation (R109C)         | Yes (3/4)    | WGS, Mauve alignment, PFGE                               | NR                                       | NR                           |
| Kim Y, 2014 [26]             | COL (n=3) <sup>f</sup>                               | E-test  | <i>pmrB</i> mutations (A227V, P233S, frame shift after Phe26)  | NR           | PFGE   | Yes (3/3)                                | Died (2 of 3 patients)       |
| Pournaras S, 2014 [27]       | COL (n=2) <sup>f</sup>                               | broth microdilution                           | <i>pmrB</i> mutations (P170L, P233S)   | Yes (2/2)    | PFGE, MLST   | No (2/2)                                 | Discharged (2/2)             |
| Durante-Mangoni E, 2015 [28] | COL (n=1) <sup>f</sup>                               | broth microdilution                           | <i>pmrB</i> mutation (P233S)   | No           | PFGE, MLST   | Yes                                      | Died                         |
| Lim TP, 2015 [29]            | PMB (n=2) <sup>f</sup>                               | broth microdilution                           | <i>pmrB</i> mutations (P233S, R263H)   | No           | WGS, SNPs phylogenetic analysis, MLST                    | NR                                       | NR                           |
| Liu L, 2016 [30]             | TGC (n=2) <sup>f</sup>                               | broth microdilution                           | Unclear <sup>j</sup>   | NR           | WGS, SNPs phylogenetic analysis, MLST                    | NR                                       | Discharged (2/2)             |
| Wright MS, 2016 [31]         | COL (n=1) <sup>g</sup>                               | broth microdilution                           | <i>pmrB</i> mutation (P154T)   | NR           | WGS, SNPs phylogenetic analysis                          | NR                                       | NR                           |

| First author, Year         | Emergent resistance to (n <sup>a</sup> );              | Method of susceptibility testing <sup>b</sup> | Mechanisms of resistance <sup>c</sup>   | Fitness cost | Molecular methods <sup>d</sup>              | Effect on treatment failure <sup>e</sup> | Outcome           |
|----------------------------|--|---|---|--------------|---|--|-------------------|
| Choi HJ, 2017 [32]         | COL (n=1) <sup>f</sup><br>TGC (n=1) <sup>f</sup>       | broth microdilution                           | <i>pmrB</i> mutations (H265Y, L239S, R263H) <sup>k</sup><br>mechanism of TGC resistance was not evaluated   | NR           | PFGE  | Yes <sup>l</sup>                         | Died <sup>l</sup> |
| Dahdouh E, 2017 [33]       | COL (n=1) <sup>f</sup><br>COL + TGC (n=1) <sup>f</sup> | E-test (COL)<br>Vitek-2 (TGC)                 | <i>pmrB</i> mutations (P233S, Δ119),<br>mechanism of TGC resistance not reported  | Yes (1/2)    | MLTS, RAPD                                  | Yes (2/2)                                | Died (1/2)        |
| Lenhard JR, 2017 [34]      | COL (n=1) <sup>f</sup>                                 | broth microdilution                           | NR  | NR           | PFGE  | NR                                       | NR                |
| Savari M, 2017 [35]        | COL (n=1) <sup>f</sup>                                 | E-test  | Unclear <sup>m</sup>  | NR           | IC, MLST, MLVA                              | NR                                       | NR                |
| Cafiso V, 2018 [36]        | COL (n=2) <sup>f</sup>                                 | broth microdilution                           | <i>pmrB</i> mutations (L208F, R263H)<br><i>lpxC</i> mutation (S171Y)<br><i>lpxD</i> mutation (truncated protein at the 292 amino acid)              | NR           | WGS, PFGE, MLST, SNPs phylogenetic analysis | NR                                       | NR                |
| Deveson Lucas D, 2018 [37] | COL (n=1) <sup>f</sup>                                 | broth microdilution                           | Insertion of IS <i>Aba125</i> resulting in inactivation of the regulatory gene <i>hns</i> and upregulation of <i>eptA</i> (a <i>pmrC</i> homologue) | No           | WGS, SNPs phylogenetic analysis             | Yes                                      | Died              |
| Farshadzeh Z, 2018 [38]    | COL (n=2) <sup>f</sup>                                 | broth microdilution                           | <i>pmrB</i> mutations (P233S, T232I)  | No (2/2)     | MLST, MLVA                                  | Yes (2/2)                                | Died (1/2)        |

| First author, Year         | Emergent resistance to (n <sup>a</sup> ); | Method of susceptibility testing <sup>b</sup> | Mechanisms of resistance <sup>c</sup>  | Fitness cost | Molecular methods <sup>d</sup>                      | Effect on treatment failure <sup>e</sup>                   | Outcome              |
|----------------------------|---|---|--|--------------|---|--|----------------------|
| Gerson S, 2018 [39]        | TGC (n=4) <sup>g</sup>                    | agar dilution                                 | insertion of <i>ISAbal</i> in <i>adeS</i><br>insertion of <i>ISAbal25</i> or<br><i>ISAbal</i> in <i>AdeN</i>   | NR           | WGS (<10 allele differences), Mauve alignment, MLST | NR   | NR                   |
| Jaidane N, 2018 [40]       | COL (n=1) <sup>f</sup>                    | broth microdilution                           | <i>pmrB</i> mutation (S1314-CILIFSVILG-duplication)  | NR           | WGS (<25 SNPs)                                      | Yes  | Discharged           |
| Mustapha MM, 2018 [41, 42] | COL (n=14) <sup>f</sup>                   | broth microdilution                           | <i>pmrB</i> mutations (R134S, T235I, A226T, T232A, F267L, L271F, Q277K, L208R, R263C, P233T, L292H, P233S, G315V)<br><i>pmrA</i> mutations (L20F, M12I) <sup>n</sup> | NR           | WGS, SNPs phylogenetic analysis, PFGE, MLST         | Yes (but unclear in how many of the patients) <sup>o</sup> | Unclear <sup>o</sup> |
| Saun TJ, 2018 [43]         | COL (n=2) <sup>f</sup>                    | NR  | NR   | NR           | PGFE  | Yes (1/2)  | Discharged (2/2)     |
| Gerson S, 2019 [44]        | COL (n=3) <sup>p</sup>                    | broth microdilution                           | <i>pmrB</i> mutations ( $\Delta$ L9-G12, I232T, S17R)<br>insertion of <i>ISAbal</i> upstream of <i>eptA</i>  | No (2/2)     | WGS (<10 allele differences)                        | NR   | NR                   |
| Cheng J, 2020 [45]         | TGC (n=1) <sup>f</sup>                    | broth dilution                                | Unclear (upregulation of efflux pumps among other proposed mechanisms)   | NR           | WGS, MLST, SNPs phylogenetic analysis               | NR   | NR                   |
| Marano V, 2020 [46]        | COL (n=3) <sup>f</sup>                    | broth microdilution                           | <i>pmrB</i> mutations (E301G, L168K, P233T)  | NR           | PFGE  | Yes (3/3)  | Died (2/3)           |

**Abbreviations;** COL= colistin, IC= international clonage lineage, MLST= multilocus sequencing typing, MLVA= multi-locus variable number tandem repeat analysis, NR= not reported, PFGE= pulsed-field gel electrophoresis, RAPD= random amplified polymorphic DNA, rep-PCR= repetitive extragenic palindromic polymerase chain reaction, PMB= polymyxin B, SNP= single nucleotide polymorphism, TGC= tigecycline, WGS= whole genome sequencing

<sup>a</sup> The number of patients with paired sensitive and resistant isolates.

- <sup>b</sup> The method of susceptibility testing used for the antibiotic to which resistance emerged (colistin or tigecycline).
- <sup>c</sup> The resulting amino acid substitutions/deletions are shown in parentheses.
- <sup>d</sup> Any molecular method that was used to confirm the same origin (vs cross-infection) of sequential *A. baumannii* isolates from the same patient.
- <sup>e</sup> Emergent resistance was considered to be responsible for treatment failure when associated with persistent or recurrent symptoms and/or sings of infection necessitating further treatment.
- <sup>f</sup> Exposure to the same antibiotic preceded the emergence of resistance.
- <sup>g</sup> Whether the patients had been exposed to colistin/tigecycline before emergence of resistance was not reported.
- <sup>h</sup> Patient with ventilator-associated pneumonia and empyema. Tigecycline resistance developed after 14 days of treatment with tigecycline and received treatment for a total of days. The patient received treatment with tigecycline for 49 days and was successfully treated.
- <sup>i</sup> Resistance to tigecycline emerged during treatment with tobramycin (potential cross-resistance by overexpression of AdeB efflux pump).
- <sup>j</sup> Resistance was attributed to a homologous recombination (including OprD, a sugar-type MFS permease, and a LuxR-type transcriptional regulator).
- <sup>k</sup> Multiple colistin-resistant strains isolates from the same patient and with different mutations conferring colistin resistance.
- <sup>l</sup> The patient died with persistent colistin-susceptible bacteremia, but all isolates demonstrated colistin-resistant subpopulations and the isolate from the endotracheal aspirate was colistin-resistant.
- <sup>m</sup> No *pmrA*/*pmrB* mutations were detected and lipopolysaccharide was intact. Colistin resistance was attributed to acquisition of two genomic regions including among other genes *ispA* and *cadA*, both of which have the potential to modify lipid A or reduce the surface negative charges.
- <sup>n</sup> In most cases mutation in either *pmrB* (n=8) or *pmrA* (2) were found. In one case a 2.3 kb deletion involving 94% of *pmrC*, all of *pmrA* and the first 44 amino acids of *pmrB* was found in the colistin-susceptible strain but not in the colistin-resistant strain. In 3 cases no *pmrA* or *pmrB* mutations were described, but an accumulation of mutations was observed in genes involved in surface structures including pilus, capsule and O antigen biosynthesis and transport.
- <sup>o</sup> In most cases (based on the first study [42]) colistin-resistant *A. baumannii* required treatment and was associated with high in-hospital mortality but the relevant data could not be extracted for the subset of the 14 patients included in this review [41].
- <sup>p</sup> Treatment with colistin preceded the development of colistin resistance in only 2 of the 3 cases.